Related references
Note: Only part of the references are listed.Aspirin Inhibits mTOR Signaling, Activates AMP-Activated Protein Kinase, and Induces Autophagy in Colorectal Cancer Cells
Farhat V. N. Din et al.
GASTROENTEROLOGY (2012)
Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials
Peter M. Rothwell et al.
LANCET (2012)
Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials
Annemijn M. Algra et al.
LANCET ONCOLOGY (2012)
Assessing Supplement Safety - The FDA's Controversial Proposal
Pieter A. Cohen
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Chemoprevention - History and general principles
Xiangwei Wu et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2011)
Phase 0 Trials: Expediting the Development of Chemoprevention Agents
Shivaani Kummar et al.
CANCER PREVENTION RESEARCH (2011)
Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Eric A. Klein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
John Burn et al.
LANCET (2011)
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Paul E. Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
Victor G. Vogel et al.
CANCER PREVENTION RESEARCH (2010)
Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis
Victoria A. Brown et al.
CANCER RESEARCH (2010)
Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis
Nicholas J. West et al.
GUT (2010)
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials
Peter M. Rothwell et al.
LANCET (2010)
Effect of Dutasteride on the Risk of Prostate Cancer.
Gerald L. Andriole et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Development of Dietary Phytochemical Chemopreventive Agents: Biomarkers and Choice of Dose for Early Clinical Trials
Edwina N. Scott et al.
CANCER PREVENTION RESEARCH (2009)
Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers The Selenium and Vitamin E Cancer Prevention Trial ( SELECT)
Scott M. Lippman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The Untapped Potential of Genetically Engineered Mouse Models in Chemoprevention Research: Opportunities and Challenges
Cory Abate-Shen et al.
CANCER PREVENTION RESEARCH (2008)
Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial
Frank L. Meyskens et al.
CANCER PREVENTION RESEARCH (2008)
Targeting Epigenetic Mechanisms: Potential of Natural Products in Cancer Chemoprevention
Alexander-Thomas Hauser et al.
PLANTA MEDICA (2008)
Finasteride and high-grade prostate cancer in the prostate cancer prevention trial
M. Scott Lucia et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies
Enrico Flossmann et al.
LANCET (2007)
Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial
Jack Cuzick et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Clinical trials with oncolytic adenovirus in China
Wang Yu et al.
CURRENT CANCER DRUG TARGETS (2007)
Free radicals and antioxidants in normal physiological functions and human disease
Marian Valko et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Development of novel cancer chemopreventive agents in Europe - Neglected Cinderella or rising phoenix? ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005
Clarissa Gerhauser et al.
EUROPEAN JOURNAL OF CANCER (2006)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial
Victor G. Vogel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Nuclear factor-κB in cancer development and progression
Michael Karin
NATURE (2006)
Mechanisms of disease: Estrogen carcinogenesis in breast cancer
JD Yager et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Overview of mechanisms of cancer chemopreventive agents
S De Flora et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2005)
Mechanisms of disease - Inflammation, atherosclerosis, and coronary artery disease
GK Hansson
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
SD Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The chemopreventive agent development research program in the division of cancer prevention of the US National Cancer Institute: An overview
JA Crowell
EUROPEAN JOURNAL OF CANCER (2005)
The influence of finasteride on the development of prostate cancer
IM Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
G Steinbach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
